Multiple myeloma: new treatments gain momentum
Mené sur 525 patients atteints d'un myélome multiple et non immédiatement éligibles à une greffe autologue de cellules souches, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du bortézomib à un traitement combinant lénalidomide et dexaméthasone
In The Lancet, Brian Durie and colleagues1 report a significant improvement in progression-free survival, overall response rate, and overall survival with the addition of bortezomib to the lenalidomide-dexamethasone combination (VRd) compared with lenalidomide and dexamethasone alone (Rd) in 525 newly diagnosed patients with multiple myeloma. Induction therapy was planned for 6 months and was followed by Rd maintenance therapy in both groups. Patients had a median age of 62 years, with 43% being 65 years or older.
The Lancet , commentaire, 2015